Against a backdrop of slowing growth in Japan’s generic drug market and declining drug prices, this theme covers entry into orphan drug development and contract services with Japan, the United States and Europe in view, including an agreement with Nobel Pharma and the clinical development and investigational drug manufacturing of NPC-29.